Beverly Koller, BS, PhD
Dr. Koller is currently an Associate Professor in the Department of Medicine, University of North Carolina, Chapel Hill (UNC), the current Director of the transgenic mouse core facility, and ex Director (1993-1999) of the UNC Embryonic Stem Cell Facility. Dr. Koller received her undergraduate degree, with honors, in biology (1980) from the University of Ottawa and her Ph.D. (pathobiology and biochemistry) in 1985 from the University of Minnesota, Minneapolis, MN. Following her graduate education, Dr. Koller was a Research Associate in pathology (1985-1987) at the University of Minnesota and in medical genetics and genetics (1978-1988) at the University of Wisconsin, Madison, WI. From 1988 through 1990, Dr. Koller was a Postdoctoral Fellow in Pathology at UNC. She joined the faculty in 1990 at UNC as an Assistant Professor in the Department of Medicine. Dr. Koller is also a member of UNC Graduate Faculty. Dr. Koller is internationally recognized for her studies on the human major histocompatibility complex and has worked and published with distinguished scientists in her field such as Dr. Fritz Bach, D., Harry T. Orr, and Dr. Oliver Smithies. Dr. Koller’s other research interests include the development of mouse models of human disease with complex etiologies (breast cancer, cystic fibrosis, and schizophrenia) and inflammation, in particular paracrine regulation of inflammation by prostaglandins and nucleotides. Her research has resulted in numerous publications (90) in peered reviewed journals. She serves on the grant review committees for National Institutes of Health and National Cancer Institute.
Adrian P. Gee, MI Biol, PhD
Dr. Adrian Gee is currently Professor of Medicine and Pediatrics at the Baylor College of Medicine in Houston, TX, and is also Director of the Clinical Applications Laboratory at the Center for Cell and Gene Therapy, also affiliated with the Baylor College of Medicine. Dr. Gee obtained his undergraduate degree from the University of Birmingham, UK in 1973, and his doctorate from the University of Edinburgh in 1977. He continued his postdoctoral training at the University of Edinburgh, National Cancer Institute (USA), and the University of Toronto, Canada. In 1982, Dr. Gee joined the faculty of the University of Florida, College of Medicine as an Assistant/Associate Professor in the Department of Pediatrics and became the Director of Research in the Division of Hematology/Oncology, Department of Pediatrics. In 1987, he joined Baxter Healthcare Corporation as a Senior Scientist in the Immunotherapy Group later becoming Manager for Research and Development. In 1992, he returned to academia as Professor of Medicine in the Division of Transplantation Medicine, University of South Carolina at Columbia, SC. In 1997, Dr. Gee left South Carolina to become Professor of Medicine and Director of the Stem Cell Processing laboratory in the Section of Blood and Marrow Transplantation, Department of Hematology, MD Anderson Cancer Center in Houston, TX. Following his tenure at the MD Anderson Cancer Center, Dr. Gee joined the faculty of the Baylor College of Medicine. Dr. Gee has served on many administrative boards throughout his career including the Florida State Board and local chapter of “Stop Childrens Cancer”, and the organizing committee for the first – fourth International Workshops on Bone Marrow Purging. He is the founder of the International Society for Hematology and Graft Engineering (ISAGE) and is also a member or the North American Task Force for the Development of Standards for Hematopoietic Cell Processing and Transplantation and has also served on numerous scientific journal editorial boards as editor-in-chief, regional editor and reviewer. Throughout his scientific career, Dr. Gee has been the recipient of many awards including the Lady Tate Fellowship (1982-1984), Wellcome Research Travel Award (1984, 1986) and the Leukemia Society of America “Triumphs through Technology Award” (1993). Dr. Gee is also a member of numerous national and international scientific societies and has published extensively in peer reviewed journals on the subjects of stem cell therapies and transplantation.
Michael D.P. Boyle, BSc (Hons), PhD
Dr. Boyle is currently the William J. von Liebig Professor of Biomedical Sciences in the Department of Biology at Juniata College in Huntingdon, Pennsylvania. Dr. Boyle received his B.Sc. (with honors) in biochemistry from the University of Glasgow, Glasgow, Scotland and his Ph.D. from the Chester Beatty Research Institute, Belmont Surrey, UK. Following his graduate education, Dr. Boyle joined the National Cancer Institute as a Visiting Fellow in the Humoral Immunity section of the Laboratory of Immunobiology. Dr. Boyle left the National Institutes of Health in 1981 to take an academic appointment as Associate Professor of Microbiology in the Department of Immunology and Medical Microbiology, College of Medicine at the University of Florida, becoming a full Professor in 1985. In 1998, Dr. Boyle took the faculty position as Professor of Immunology in the Department of Medical Microbiology and Immunology at the Medical College of Ohio, Toledo, OH. He also served as Executive Director of the NW Ohio Life Sciences Incubator and Director of the Pathogenesis and Immunology program of the Medical College of Ohio Cancer Initiative. Dr. Boyle has also served on numerous editorial boards for scientific journals as editor and reviewer. He has also been a member of various National Institutes of Health (NIH), National Science Foundation (NSF) and American Heart Association (AHA) grant study sections. Dr. Boyle is nationally and internationally recognized for his research in the areas of bacterial FC-binding proteins, wound healing, immunochemistry, and molecular pathogenesis having published 190 scientific articles in these areas and having been the recipient of extramurially funded grants from NIH, NSF, ACS, AHA and industry. Dr. Boyle holds 13 US patents on discoveries resulting from his studies. Dr. Boyle is also the founder and President of Gator Microbiologicals, Inc. (now Receptor Pro) a privately held biotechnology company that specializes in the commercialization of bacterial FC-binding proteins and other important bacterial antigens.
Alan Hardwick, PhD
Dr. Hardwick has 17 years experience in biomedical process and product development. Most recently he served as Director, Cell Processing at Xcyte Therapies, Inc., a Seattle-based biotechnology company focused on cellular therapies. In this capacity, he directed the development and documentation of a closed-system, large-scale process for preparing, culturing, harvesting and shipping of patient T-cells for use in adoptive immunotherapy protocols. From 1983 to 1998 Dr. Hardwick held several positions at Baxter Healthcare Corporation and was, most recently, Associate Director, Cell Processing Systems in the Immunotherapy Division. In this position he started or refined large-scale blood cell processes, involving cell collection, purification, transduction, expansion and storage, to support gene therapy or cell therapy clinical trials in the U.S., Europe and Japan. He also served as Senior Principal Engineer and Engineering Manager in the Immunotherapy Division and as Principal Engineer in the Fenwal Division of Baxter Healthcare Corporation. He holds a Ph.D. in Chemical Engineering from Rice University, a M.S. in Chemical Engineering from the University of Illinois and a B.S. in Chemical Engineering from Washington University.
Charles Bagwell, MD
Dr. Bagwell has been Professor and Chairman, Division of Pediatric Surgery at Virginia Commonwealth University in Richmond Virginia since 1993. He received his undergraduate degree in 1968 from Wake Forest University, Winston-Salem, N.C., and his medical degree from Bowman Gray School of Medicine, Winston-Salem, N.C. in 1972. Dr. Bagwell also served as a Surgical Intern at University of Virginia Hospital, a Surgical Resident at the University of Virginia, a Surgical Fellow at the Hospital for Sick Children, Toronto, Ontario, and was Chief Resident in Pediatric Surgery at the Hospital for Sick Children. Dr. Bagwell holds the Certificate of Special Competence Critical Care in Surgery and the Certificate of Special Competence Pediatric Surgery in Laser Surgery. His clinical interests include Laser Surgery, Airway Surgery in Children, Pediatric Solid Tumors, and International Health Care for Children. Currently, he is coordinating divisional research efforts in the area of fetal wound healing. His plans for Pediatric Surgery at Virginia Commonwealth are to develop investigative techniques regarding solid tumors in children, grown both in cell culture and in experimental animals. Research in this area will focus on specific growth factors as well as operative procedures to reduce tumor bulk or prevent local tumor recurrence.